Mesa Laboratories Holds Annual Shareholder Meeting: Directors Elected, Committees Appointed, and Financial Management Demonstrated.

Mesa Laboratories held its annual shareholder meeting on August 22, 2025, where 5,203,377 shares were represented. The election of directors was confirmed, and the board appointed members to its committees. Shareholders also ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. The compensation of the company's named executive officers was approved on a non-binding basis, and an amendment to the 2021 Equity Incentive Plan was also approved.

Mesa Laboratories, Inc. (NASDAQ: MLAB) has executed its previously announced strategic financial plan, repaying $97.5 million in aggregate principal of its 1.375% Convertible Senior Notes due August 2025. On August 12, 2025, the company drew $97.0 million under its existing Amended and Restated Credit Agreement, bringing the total outstanding balance to $108 million. The proceeds were used to settle the 2025 Notes that matured on August 15, 2025 [1].

The transaction reflects Mesa's disciplined execution of a plan communicated in April 2024. John Sakys, Chief Financial Officer, stated, "We’ve taken deliberate steps to optimize our capital structure using our Credit Facility, reducing potential dilution to our shareholders from the use of a hybrid debt instrument while supporting Mesa’s long-term growth." The interest rate on the Credit Facility, currently 7.18%, will decrease in line with future Federal Funds Rate reductions, with an additional 25 basis point reduction triggered when Mesa’s net leverage ratio falls below 3.0x, expected by the third quarter of this fiscal year. Interest payments for the second quarter of fiscal year 2026 are expected to be approximately $2.7 million, with payments of $3.1 million or lower in each quarter thereafter [1].

Mesa Laboratories held its annual shareholder meeting on August 22, 2025, where 5,203,377 shares were represented. The election of directors was confirmed, and the board appointed members to its committees. Shareholders also ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. The compensation of the company's named executive officers was approved on a non-binding basis, and an amendment to the 2021 Equity Incentive Plan was also approved [2].

Mesa Laboratories remains committed to prudent financial management and delivering value to shareholders through strategic execution and operational discipline. The company continues to be a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries [1].

References:
[1] https://www.biospace.com/press-releases/mesa-laboratories-executes-previously-announced-strategic-financing-plan
[2] (Provided writing topic)